Aileron Therapeutics Inc (ALRN)
3.66
-0.05
(-1.35%)
USD |
NASDAQ |
May 08, 15:52
Aileron Therapeutics Research and Development Expense (Quarterly): 1.972M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 1.972M |
| September 30, 2023 | 0.022M |
| June 30, 2023 | 0.187M |
| March 31, 2023 | 1.81M |
| December 31, 2022 | 2.402M |
| September 30, 2022 | 4.239M |
| June 30, 2022 | 5.433M |
| March 31, 2022 | 5.893M |
| December 31, 2021 | 4.561M |
| September 30, 2021 | 4.278M |
| June 30, 2021 | 3.853M |
| March 31, 2021 | 4.316M |
| December 31, 2020 | 1.925M |
| September 30, 2020 | 2.684M |
| June 30, 2020 | 2.488M |
| March 31, 2020 | 4.069M |
| Date | Value |
|---|---|
| December 31, 2019 | 4.71M |
| September 30, 2019 | 4.475M |
| June 30, 2019 | 4.304M |
| March 31, 2019 | 4.174M |
| December 31, 2018 | 3.961M |
| September 30, 2018 | 4.321M |
| June 30, 2018 | 5.32M |
| March 31, 2018 | 4.846M |
| December 31, 2017 | 4.311M |
| September 30, 2017 | 3.825M |
| June 30, 2017 | 3.161M |
| March 31, 2017 | 2.942M |
| December 31, 2016 | 3.092M |
| September 30, 2016 | 2.605M |
| June 30, 2016 | 2.086M |
| March 31, 2016 | 2.493M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.022M
Minimum
Sep 2023
5.893M
Maximum
Mar 2022
3.348M
Average
4.069M
Median
Mar 2020
Research and Development Expense (Quarterly) Benchmarks
| EyePoint Pharmaceuticals Inc | 17.95M |
| INVO Bioscience Inc | 0.0059M |
| Bio-Path Holdings Inc | 2.276M |
| SINTX Technologies Inc | 1.824M |
| NovaBay Pharmaceuticals Inc | 0.004M |